OncoRisk Panel
Comprehensive and Specialized Hereditary Cancer Panel
Overview
Analysis of Inherited Oncogenes
Celemics’ OncoRisk panel is specifically designed to analyze hereditary cancer associated genes. The OncoRisk panel is a hereditary cancer panel that targets 31 well-known oncogenes, leading to a reduction of total sequencing cost compared to whole genome sequencing or whole exome sequencing. Additionally, if the gene of interest does not exist on the panel, it can be added separately through our gene add-on service. This flexible design provides cost-effective sequencing results to every customer.

Comprehensive Analysis of Oncogenes
The panel consists of 31 oncogenes associated with inherited cancer precisely selected from Contract Research Organizations and numerous research studies. Owing to Celemics’ proprietary probe design and manufacture technology, hereditary cancer panel demonstrates industry-leading performance with superior sensitivity and specificity compared to other competitor products in the market.

Robust Bioinformatics System for Large Deletion Analysis
At Celemics, we provide results for large deletion analysis supported by Celemics proprietary bioinformatics analysis system. We also complement this bioinformatics solution with user-friendly customizable solutions, like CNV or any other novel variant analyses.
NGS for Homologous Recombination Deficiency (HRD) Testing
Celemics’ hereditary cancer panel provides information for HRD grade computation to aid precision medicine for tumor treatment with 99.9% and 99.5% specificity for SNV and Indel, respectively. It can also detect all types of mutations with over 95% of sensitivity at 5% VAF.
Example of variants and CNV analysis results
- This example of variant analysis results include AA change, mutation type, total sequencing depth, allele frequency, etc.
Gene | Mutation Type | Amino Acid Change | Total Depth | REF Depth | ALT Depth | Variant Allele Frequency |
---|---|---|---|---|---|---|
APC | SYN | p.S1738S | 1008 | 590 | 415 | 41.17% |
ATM | Non-SYN | p.D1853N | 417 | 200 | 217 | 52.04% |
BARD1 | Non-SYN | p.R658C | 829 | 435 | 394 | 47.53% |
BMPR1A | Non-SYN | p.P2T | 621 | 309 | 311 | 50.08% |
BRCA1 | SYN | p.S1389S | 802 | 460 | 342 | 42.64% |
BRCA2 | SYN | p.V2171V | 1026 | 0 | 1026 | 100% |
BRIP1 | SYN | p.Y1137Y | 844 | 3 | 840 | 99.53% |
PMS2 | NON-SYN | K541E | 686 | 0 | 646 | 100% |
PRSS1 | SYN | p.N246N | 921 | 0 | 921 | 100% |
RAD51D | NON-SYN | p.R53Q | 971 | 0 | 971 | 100% |
Specification
Gene count* | 31 genes |
---|---|
Covered region | Whole CDS |
Target size | 96 Kb |
Mutation type | SNV, Indel, CNV, Rearrangement |
Sample type | Blood (> 50 ng of fragmented DNA), FFPE |
Platform | All sequencers from Illumina, Thermo Fisher, MGI, PacBio, and Oxford Nanopore |
Sensitivity | > 95% for all variant types at 5% VAF |
Specificity | 99.90%(SNV), 99.50%(Indel) |
Bioinformatics Support | ① Primary Analysis: FASTQ to annotated VCF ② Secondary Analysis: CNV, Large InDel ③ Tertiary Analysis: Clinical interpretation |
Specification - Gene List
Gene List |
APC | ATM | BARD1 | BLM | BMPR1A | BRCA1 | BRCA2 | BRIP1 |
---|---|---|---|---|---|---|---|---|
CDH1 | CDK4 | CDKN2A | CHEK2 | EPCAM | MLH1 | MRE11A | MSH2 | |
MSH6 | MUTYH | NBN | PALB2 | PMS2 | PRSS1 | PTEN | RAD50 | |
RAD51C | RAD51D | SLX4 | SMAD4 | STK11 | TP53 | VHL |
Related Products
Comprehensive NGS panel for identifying and characterizing the molecular fingerprint for solid tumors with market-leading sensitivity
Highly optimized, user- convenient NGS library preparation kit for all Celemics panels
Incomparable quality magnetic bead for simple, flexible, and reproducible purification

Comprehensive NGS panel for identifying and characterizing the molecular fingerprint for solid tumors with market-leading sensitivity

Highly optimized, user- convenient NGS library preparation kit for all Celemics panels

End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis

Incomparable quality magnetic bead for simple, flexible, and reproducible purification
Resources
Technical Resources
[Product Sheet] OncoRiskPanel
[Product Overview] Celemics Target Enrichment Panel Overview
[Catalogue] Celemics Products & Service Catalogue_All Products & Service
Safety Data Sheets
If you require the latest MSDS file, please contact us via ‘Contact Us‘.
MSDS_OncoRisk Panel_Illumina
MSDS_OncoRisk Panel_Thermo Fisher
MSDS_OncoRisk Panel_MGI
References
Cancer Research and Treatment
Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
Koo DH, Jung M, Kim YH, Jeung HC, Zang DY, Bae WK, Kim H, Kim HS, Lee CK, Kwon WS, Chung HC. Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13). Cancer Research and Treatment. 2024 Apr 29.
10.4143/crt.2023.1324
Summary | celemics publications
#Oncology
#ctDNA Sample
# AlphaLiquid® 100 Panel
Purpose
Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), HER2, and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC).
Result
Genomic alteration landscape in circulating tumor DNA analysis according to the progression-free survival (PFS), overall survival (OS), and EGFR/HER2 immunohistochemical expression (n=15).
Conclusion
A combination of varlitinib and paclitaxel displayed manageable toxicity and modest antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy.
Method
The circulating tumor DNA (ctDNA) was extracted from the patient’s plasma (10 mL) at two time points (before treatment and at the first response evaluation or end of the treatment). The DNA NGS library and solution-based target enrichment were performed at IMBdx, Inc. (Seoul, Korea), using AlphaLiquid100. The captured DNA libraries were sequenced using the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA) in the 2×150 bp paired-end mode.
Related Product
Circulating Tumor DNA Panel for
Colorectal / Lung / Breast Cancer
The circulating tumor DNA (ctDNA) was extracted from the patient’s plasma (10 mL) at two time points (before treatment and at the first response evaluation or end of the treatment). The DNA NGS library and solution-based target enrichment were performed at IMBdx, Inc. (Seoul, Korea), using AlphaLiquid100. The captured DNA libraries were sequenced using the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA) in the 2×150 bp paired-end mode.
Colorectal Cancer | ||
---|---|---|
Sensitivity | Freq. 0.5% | 100% |
Freq. 1.0% | 100% | |
Specificity | 97.9% |
Breast Cancer | ||
---|---|---|
Sensitivity | Freq. 0.5% | 94.4% |
Freq. 1.0% | 100% | |
Specificity | 96.3% |
Lung Cancer | ||
---|---|---|
Sensitivity | Freq. 0.5% | 100% |
Freq. 1.0% | 100% | |
Specificity | 100% |
Cancers
Discovery and Validation of Survival-Specific Genes in Papillary Renal Cell Carcinoma Using a Customized Next-Generation Sequencing Gene Panel
Hwang J, Bang S, Choi MH, Hong SH, Kim SW, Lee HE, Yang JH, Park US, Choi YJ. Discovery and Validation of Survival-Specific Genes in Papillary Renal Cell Carcinoma Using a Customized Next-Generation Sequencing Gene Panel. Cancers. 2024 Jan;16(11):2006.
10.3390/cancers16112006
Frontiers in Neurology
Case report: Compound heterozygous variants detected by next-generation sequencing in a Tunisian child with ataxia-telangiectasia
Ammous-Boukhris N, Abdelmaksoud-Dammak R, Ben Ayed-Guerfali D, Guidara S, Jallouli O, Kamoun H, Charfi Triki C, Mokdad-Gargouri R. Case report: Compound heterozygous variants detected by next-generation sequencing in a Tunisian child with ataxia-telangiectasia. Frontiers in Neurology. 2024 May 31;15:1344018.
10.3389/fneur.2024.1344018
Scientific Reports
Sex-specific survival gene mutations are discovered as clinical predictors of clear cell renal cell carcinoma
Hwang J, Lee HE, Han JS, Choi MH, Hong SH, Kim SW, Yang JH, Park U, Jung ES, Choi YJ. Sex-specific survival gene mutations are discovered as clinical predictors of clear cell renal cell carcinoma. Scientific Reports. 2024 Jul 9;14(1):15800.
10.1038/s41598-024-66525-9